Bright Uro raises oversubscribed $32M Series A

Bright Uro, a medical device company dedicated to advancing care for lower urinary tract symptoms (LUTS) through innovative urodynamic solutions, announced the second close of its Series A funding, raising a total of $32 million—an oversubscription by nearly 40%. Laborie Medical Technologies (Laborie), a global leader in urology diagnostics, continues as the lead investor, with new backing from UC Investments, Freepoint Capital Group, and Laurelin Investors.

The funds will support the planned 2025 launch of Bright Uro’s Glean™ Urodynamics System, designed to improve diagnostic capabilities for LUTS. Additionally, the investment will enable the company to expand manufacturing capacity and enhance R&D efforts, fueling future innovations in its product pipeline. This funding marks a significant milestone in Bright Uro’s mission to transform urodynamic care, with strong support from prominent investors focused on advancing urology solutions.

“The Glean system has the potential to significantly impact the urodynamics landscape, and we remain very supportive of the Bright Uro team,” said Michael Frazzette, President and CEO of Laborie. “This funding round will help enable improved patient and clinician access to the technology which directly aligns with Laborie’s mission of preserving and restoring human dignity.”

“The overwhelming interest from a diverse range of sophisticated investors is a true testament to the compelling mission we are on,” said Derek Herrera, founder and CEO of Bright Uro. “With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues.”

About Bright Uro

Based in Irvine, Calif., Bright Uro’s mission is to transform care of lower urinary tract symptoms (LUTS) with its innovative technology that is poised to disrupt outdated urodynamics approaches. The Company’s 510(k)-pending Glean™ Urodynamics System is designed to enable wireless, catheter-free urodynamics monitoring, with the ultimate goal of improving patient comfort and clinical outcomes. For more information, visit www.brighturo.com.